高危弥漫性WHO II级胶质瘤患者辅助治疗的影响
该回顾性研究纳入309例符合RTOG 9802标准的高危WHO II级胶质瘤成人患者(1997-2008年),评估历史辅助治疗与放化疗(CRT)的结局。中位随访10.6年,多因素分析显示CRT较单纯放疗改善无进展生存和总生存,较观察改善无进展生存。研究证实放疗基础上加化疗的获益,强调高危低级别胶质瘤需积极治疗。
要点
- 高危WHO II级胶质瘤中,放化疗较单纯放疗改善无进展生存和总生存。
- 放化疗较术后观察改善无进展生存。
- 组织学、分子分组和切除程度与无进展生存和总生存显著相关。
核心结论
- 本研究证实高危WHO II级胶质瘤患者放疗基础上加化疗较单纯放疗或观察有获益。
- 作者认为这些发现强调高危低级别胶质瘤患者需要积极治疗。
研究设计与样本
- 回顾性分析309例1997-2008年诊断为WHO II级胶质瘤的成人患者记录,符合RTOG 9802入组条件(不完全切除/活检或年龄≥40岁)。
- 采用Kaplan-Meier法估计无进展生存和总生存,Cox比例风险模型进行单因素和多因素风险比估计。
- 中位随访10.6年。
主要发现
- 辅助治疗分布:单纯放疗45%,观察31%,放化疗21%,单纯化疗3%。
- 单因素分析中,非星形细胞组织学、TERT启动子突变、1p/19q共缺失和广泛切除与无进展生存和总生存改善相关(均p < 0.05)。
- 单因素分析中,IDH突变和辅助放化疗与无进展生存改善相关(均p < 0.05)。
- 多因素分析中,组织学、分子分组和切除程度与无进展生存和总生存显著相关。
- 多因素分析显示,放化疗较单纯放疗改善无进展生存和总生存,较观察改善无进展生存。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Despite recent randomized, prospective evidence supporting use of RT and chemotherapy (CRT) for high-risk low-grade gliomas (LGG), many patients have historically received RT alone, chemotherapy alone or observation postoperatively. The purpose of this study is to evaluate outcomes for historical treatments in comparison to CRT for high-risk diffuse WHO grade II glioma patients. Records from 309 adults with WHO grade II glioma (1997-2008) eligible for RTOG 9802 (incomplete resection/biopsy or age ≥40 years) were retrospectively reviewed. Kaplan-Meier estimates were used for progression-free survival (PFS) and overall survival (OS). The Cox proportional hazards model was used for estimates of risk ratios for univariate and multivariate analyses. Median follow-up was 10.6 years. Adjuvant treatments included radiotherapy (RT) alone (45%), observation (31%), CRT (21%) and chemotherapy alone (3%). Non-astrocytic histology, TERT promoter mutation, 1p/19q codeletion and extensive resections were associated with improved PFS and OS on univariate analysis (all p < 0.05). IDH mutations and adjuvant CRT was associated with improved PFS (all p < 0.05). On multivariate analysis, histology, molecular grouping and extent of resection were significantly associated with PFS and OS. In addition, multivariate analysis revealed that CRT was associated with improved PFS and OS compared with RT alone, and improved PFS compared with observation. This study confirms the benefit of adding chemotherapy to RT compared with RT alone or observation. These findings emphasize the need for aggressive treatment in patients with high-risk LGG.
引用
- Youland RS, Kreofsky CR, Schomas DA, et al. The impact of adjuvant therapy for patients with high-risk diffuse WHO grade II glioma. J Neurooncol. 2017. PMID: 28836106. doi:10.1007/s11060-017-2599-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。